Novel ZAP-70-Related Immunodeficiency Presenting with Epstein–Barr Virus Lymphoproliferative Disorder and Hemophagocytic Lymphohistiocytosis

<div>PET/CT comparison after 4 weekly dose of rituximab. Pretreatment PET/CT (a) showing FDG-avid splenomegaly. PET/CT after 4 weekly doses of rituximab 375 mg/m<sup>2</sup> (b), demonstrating a complete response.</div>

Case Reports in Immunology

fig1

Figure 1

Figure 1: Novel ZAP-70-Related Immunodeficiency Presenting with Epstein–Barr Virus Lymphoproliferative Disorder and Hemophagocytic Lymphohistiocytosis 

Figure 1 | Novel ZAP-70-Related Immunodeficiency Presenting with Epstein–Barr Virus Lymphoproliferative Disorder and Hemophagocytic Lymphohistiocytosis 